Update-1 Five days of selling but looks like routine re-balancing at market highs.

  • NASDAQ leads way down 0.7%

Whether it is concerns about Washington or a seasonal buyers strike or even an extended summer vacation who knows? The 3.3% drop in AAPL on App Store ruling did not help. Here are some winners today among our small cap focus stocks: Cryoport (CYRX), Editas (EDIT) and Quidel (QDEL) . Regeneron (REGN) stopped a short slide up 0.68% to $650 but many large cap biopharma stocks  were sluggish. COVID testing stocks were up even long time laggards (OSUR) continuing an upward trend.

United Health (UNH) took a 2.57% hit to $403.91 close to $400 support.

The IBB held at $173 level but down 1.57% over five days. COVID vaccine stocks were flattish. Volatile VIR was up 4.42% on their monoclonal COVID therapy portfolio.

in a bright spot chip stocks were many up.

Small Cap Biotechs Sagging 

Despite record highs in the NASDAQ recently at the 15,000 level the biotech market seems sluggish. Speculation has ebbed. As if we need a green screen every day. But as people get back to work and Q3 earnings come out in October the direction of the market should get clarified. We need positive business news to drive markets against a backdrop of global malaise of delta variant spikes, a potential GDP slowdown and concerns about inflation. Moreover the so called “reopening rally” is fading with cyclical stocks down over the past month.

Still we have few winners lately and small M&A deals. Kadmon Holdings  (KDMN) was up over 70% today to $9.15 as the French drugmaker Sanofi (SNF) bought the Company for $1.9B to bolster its transnplant portfolio. Kadmon is focused in graft-versus-host disease and their lead product Resurock was recently approved by the FDA. Kadmon stock started moving from the $4 level in early August.

Small Cap Biotechs Sag But Provide Innovation Over the Long Term

Momentum for small caps peaked in February 2021. Here are three ETFS that correlate with small cap performance.

All of our small cap focus picks have been weak lately and are up today: CRSP, CYRX and VCYT. All are doing well since we bought them in May. Veracyte (VCYT) is up 45% over 3 months. We have a new position in Quidel (QDEL) that is up over 5% to $140 on expanded COVID testing.

Biotech innovation is key to future market gains and the genomics product potential has just begun as shown with mRNA vaccines.

Gene therapy stocks are all up today as clinical data continues to roll out. Many are down 40% off their highs but are all excellent trading vehicles.

Diversification is Key to Portfolio Management

Sector performance outside healthcare is volatile due to a slower growth forecast and the delta variant. Energy (XLE) and materials (XLB) are lagging. Expectations are higher for Financials (XLF) and Consumer Staples (XLP) due to their relatively defensive holdings.

Review our previous posts focused on biotech and healthcare . Two ETFs were key to our performance in 2021: IBB up 15.8% and XLV up 19.6% YTD. United Health (UNH) is up 19.4% YTD but relatively flat since early May. Large cap biopharma has carried us in 2021 because of modest growth plus dividends. But in early am trading large caps are weak presumably to concerns yet again about drug pricing legislation. Here is a pro-biotech industry article and letter which outlines concerns about government dictated dug pricing via Medicare. If biotechs are to regain favor we need to see small cap action to pick up and this requires more dealmaking.


Pin It on Pinterest